Document:

Exhibit 10.46

  

NEITHER
THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON
STOCK PURCHASE WARRANT

 

BIOXYTRAN, INC.

 

Warrant
Shares: 50,000

Date
of Issuance: January 10, 2020 (“Issuance Date”)

 

This
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the issuance
of the convertible promissory note in the principal amount of $125,000.00 to the Holder (as defined below) of even date) (the
“Note”), EMA Financial, LLC, a Delaware limited liability company (including any permitted and registered assigns,
the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date of issuance hereof, to purchase from BIOXYTRAN, INC., a Nevada corporation (the “Company”),
up to 50,000 shares of Common Stock (as defined below) (the “Warrant Shares”) (whereby such number may be adjusted
from time to time pursuant to the terms and conditions of this Warrant) at the Exercise Price per share then in effect. This Warrant
is issued by the Company as of the date hereof in connection with that certain securities purchase agreement dated January 10,
2020, by and among the Company and the Holder (the “Purchase Agreement”).

 

Capitalized
terms used in this Warrant shall have the meanings set forth in the Purchase Agreement unless otherwise defined in the body of
this Warrant or in Section 12 below. For purposes of this Warrant, the term “Exercise Price” shall mean $2.00,
subject to adjustment as provided herein (including but not limited to cashless exercise), and the term “Exercise Period”
shall mean the period commencing on the Issuance Date and ending on 5:00 p.m. eastern standard time on the five-year anniversary
thereof.

  

    1

     

    

 

1. EXERCISE
OF WARRANT.

 

(a)
 Mechanics of Exercise. Subject to the terms and conditions hereof, the rights
represented by this Warrant may be exercised in whole or in part at any time or times during the Exercise Period by delivery of
a written notice, in the form attached hereto as Exhibit A (the “Exercise Notice"), of the Holder’s
election to exercise this Warrant. The Holder shall not be required to deliver the original Warrant in order to effect an exercise
hereunder. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal
to the applicable number of Warrant Shares purchased. On or before the second Trading Day (the “Warrant Share Delivery
Date") following the date on which the Holder sent the Exercise Notice to the Company or the Company’s transfer
agent, and upon receipt by the Company of payment to the Company of an amount equal to the applicable Exercise Price multiplied
by the number of Warrant Shares as to which all or a portion of this Warrant is being exercised (the “Aggregate Exercise
Price” and together with the Exercise Notice, the “Exercise Delivery Documents”) in cash or by wire
transfer of immediately available funds (or by cashless exercise, in which case there shall be no Aggregate Exercise Price provided),
the Company shall (or direct its transfer agent to) issue and dispatch by overnight courier to the address as specified in the
Exercise Notice, a certificate, registered in the Company’s share register in the name of the Holder or its designee, for
the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise (or deliver such shares of Common
Stock in electronic format if requested by the Holder). Upon delivery of the Exercise Delivery Documents, the Holder shall be
deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant
has been exercised, irrespective of the date of delivery of the certificates evidencing such Warrant Shares. If this Warrant is
submitted in connection with any exercise and the number of Warrant Shares represented by this Warrant submitted for exercise
is greater than the number of Warrant Shares being acquired upon an exercise, then the Company shall as soon as practicable and
in no event later than three Business Days after any exercise and at its own expense, issue a new Warrant (in accordance with
Section 6) representing the right to purchase the number of Warrant Shares purchasable immediately prior to such exercise under
this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised.

 

If
the Company fails to cause its transfer agent to transmit to the Holder the respective shares of Common Stock by the respective
Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise in Holder’s sole discretion, and
such failure shall be deemed an event of default under the Note.

 

If
the Market Price of one share of Common Stock is greater than the Exercise Price, the Holder may elect to receive Warrant Shares
pursuant to a cashless exercise, in lieu of a cash exercise, equal to the value of this Warrant determined in the manner described
below (or of any portion thereof remaining unexercised) by surrender of this Warrant and a Notice of Exercise, in which event
the Company shall issue to Holder a number of Common Stock computed using the following formula:

 

X
= Y (A-B)

     A

 

Where
X = the number of Shares to be issued to Holder.

 

Y
= the number of Warrant Shares that the Holder elects to purchase under this Warrant (at the date of such  calculation).

 

A
= the Market Price (at the date of such calculation).

 

B
= Exercise Price (as adjusted to the date of such calculation).

 

(b)
 No Fractional Shares. No fractional shares shall be issued upon the exercise
of this Warrant as a consequence of any adjustment pursuant hereto. All Warrant Shares (including fractions) issuable upon exercise
of this Warrant may be aggregated for purposes of determining whether the exercise would result in the issuance of any fractional
share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance
of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash equal to the product resulting from
multiplying the then-current fair market value of a Warrant Share by such fraction.

  

    2

     

    

 

(c)
 Holder’s Exercise Limitations. The Company shall not effect any
exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, to the extent that
after giving effect to issuance of Warrant Shares upon exercise as set forth on the applicable Notice of Exercise, the Holder
(together with the Holder’s Affiliates, and any other persons acting as a group together with the Holder or any of the
Holder’s Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation, as defined below. For
purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates
shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such
determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise
of the remaining, non-exercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates and (ii)
exercise or conversion of the unexercised or non-converted portion of any other securities of the Company (including without
limitation any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation
contained herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence,
for purposes of this paragraph (d), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange
Act, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in
compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed
in accordance therewith. To the extent that the limitation contained in this paragraph applies, the determination of whether
this Warrant is exercisable (in relation to other securities owned by the Holder together with any affiliates) and of which
portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of
Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable, in each
case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm
the accuracy of such determination.

 

For
purposes of this paragraph, in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of
outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the
Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the
Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the request of a Holder, the
Company shall within two Trading Days confirm to the Holder the number of shares of Common Stock then outstanding. In any case,
the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities
of the Company, including this Warrant, by the Holder or its affiliates since the date as of which such number of outstanding
shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of
shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon
exercise of this Warrant. Upon no fewer than 61 days’ prior notice to the Company, a Holder may increase or decrease the
Beneficial Ownership Limitation provisions of this paragraph, provided that the Beneficial Ownership Limitation in no event exceeds
9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock upon exercise of this Warrant held by the Holder and the provisions of this paragraph shall continue to apply. Any such
increase or decrease will not be effective until the 61st day after such notice is delivered to the Company and shall only apply
to such Holder and no other Holder. The limitations contained in this paragraph shall apply to a successor Holder of this Warrant.

  

    3

     

    

  

2.
 ADJUSTMENTS. The Exercise Price and the number of Warrant Shares shall be adjusted
from time to time as follows:

 

(a)
 Distribution of Assets. If the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including without limitation any distribution of cash, stock or other securities, property or options by way of
a dividend, spin off, reclassification, corporate rearrangement or other similar transaction) (a “Distribution”),
at any time after the issuance of this Warrant, then, in each such case:

 

(i)
 any Exercise Price in effect immediately prior to the close of business on the record
date fixed for the determination of holders of shares of Common Stock entitled to receive the Distribution shall be reduced, effective
as of the close of business on such record date, to a price determined by multiplying such Exercise Price by a fraction (i) the
numerator of which shall be the Closing Sale Price of the shares of Common Stock on the Trading Day immediately preceding such
record date minus the value of the Distribution (as determined in good faith by the Company’s Board of Directors) applicable
to one share of Common Stock, and (ii) the denominator of which shall be the Closing Sale Price of the shares of Common Stock
on the Trading Day immediately preceding such record date; and

 

(ii)
 the number of Warrant Shares shall be increased to a number of shares equal to the number
of shares of Common Stock obtainable immediately prior to the close of business on the record date fixed for the determination
of holders of shares of Common Stock entitled to receive the Distribution multiplied by the reciprocal of the fraction set forth
in the immediately preceding clause (i); provided, however, that in the event that the Distribution is of shares of common stock
of a company (other than the Company) whose common stock is traded on a national securities exchange or a national automated quotation
system (“Other Shares of Common Stock”), then the Holder may elect to receive a warrant to purchase Other Shares
of Common Stock in lieu of an increase in the number of Warrant Shares, the terms of which shall be identical to those of this
Warrant, except that such warrant shall be exercisable into the number of shares of Other Shares of Common Stock that would have
been payable to the Holder pursuant to the Distribution had the Holder exercised this Warrant immediately prior to such record
date and with an aggregate exercise price equal to the product of the amount by which the exercise price of this Warrant was decreased
with respect to the Distribution pursuant to the terms of the immediately preceding clause (i) and the number of Warrant Shares
calculated in accordance with the first part of this clause (ii).

  

    4

     

    

 

(b)
 Anti-Dilution Adjustments to Exercise Price. If the Company or any
Subsidiary thereof, as applicable, at any time while this Warrant is outstanding, shall sell or grant any option to purchase,
or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to
purchase or other disposition) any Common Stock or securities entitling any person or entity to acquire shares of Common
Stock (upon conversion, exercise or otherwise) (including but not limited to under the Note), at an effective price per share
less than the then Exercise Price (such lower price, the “Base Share Price” and such issuances
collectively, a “Dilutive Issuance”) (if the holder of the Common Stock or Common Stock Equivalents so
issued shall at any time, whether by operation of purchase price adjustments, elimination of an applicable floor price for
any reason in the future (including but not limited to the passage of time or satisfaction of certain condition(s)), reset
provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share
which are issued in connection with such issuance, be entitled or potentially entitled to receive shares of Common Stock at
an effective price per share which is less than the Exercise Price at any time while such Common Stock or Common Stock
Equivalents are in existence, such issuance shall be deemed to have occurred for less than the Exercise Price on such date of
the Dilutive Issuance (regardless of whether the Common Stock or Common Stock Equivalents are (i) subsequently redeemed or
retired by the Company after the date of the Dilutive Issuance or (ii) actually converted or exercised at such Base Share
Price), then the Exercise Price shall be reduced at the option of the Holder and only reduced to equal the Base Share Price,
and the number of Warrant Shares issuable hereunder shall be increased such that the aggregate Exercise Price
payable hereunder, after taking into account the decrease in the Exercise Price, shall be equal to the aggregate Exercise
Price prior to such adjustment (for the avoidance of doubt, the aggregate Exercise Price prior to such adjustment is
calculated as follows: the total number of Warrant Shares issuable upon exercise of this Warrant immediately prior to such
adjustment (without regard to the Beneficial Ownership Limitation) multiplied by the Exercise Price in effect immediately
prior to such adjustment). By way of example, if E is the total number of Warrant Shares issuable upon exercise of this
Warrant immediately prior to such adjustment (without regard to the Beneficial Ownership Limitation), F is the Exercise Price
in effect immediately prior to such adjustment, and G is the Base Share Price, the adjustment to the number of Warrant Shares
can be expressed in the following formula: Total number of Warrant Shares after such Dilutive Issuance = the number obtained
from dividing [E x F] by G. Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued,
regardless of whether the Common Stock or Common Stock Equivalents are (i) subsequently redeemed or retired by the Company
after the date of the Dilutive Issuance or (ii) actually converted or exercised at such Base Share Price by the holder
thereof (for the avoidance of doubt, the Holder may utilize the Base Share Price even if the Company did not actually issue
shares of its common stock at the Base Share Price under the respective Common stock Equivalents). The Company shall notify
the Holder in writing, no later than the Trading Day following the issuance of any Common Stock or Common Stock Equivalents
subject to this Section 2(b), indicating therein the applicable issuance price, or applicable reset price, exchange price,
conversion price and other pricing terms (such notice the “Dilutive Issuance Notice”). For purposes of
clarification, whether or not the Company provides a Dilutive Issuance Notice pursuant to this Section 2(b), upon the
occurrence of any Dilutive Issuance, after the date of such Dilutive Issuance the Holder is entitled to receive a number
of Warrant Shares based upon the Base Share Price regardless of whether the Holder accurately refers to the Base Share Price
in the Notice of Exercise.

 

(c)
 Subdivision or Combination of Common Stock. If the Company at any time on or
after the Issuance Date subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of
its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such
subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased. If the Company
at any time on or after the Issuance Date combines (by combination, reverse stock split or otherwise) one or more classes of its
outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect immediately prior to such combination
will be proportionately increased and the number of Warrant Shares will be proportionately decreased. Any adjustment under this
Section 2(c) shall become effective at the close of business on the date the subdivision or combination becomes effective. Each
such adjustment of the Exercise Price shall be calculated to the nearest one-hundredth of a cent. Such adjustment shall be made
successively whenever any event covered by this Section 2(c) shall occur.

 

3.
 FUNDAMENTAL TRANSACTIONS. If, at any time while this Warrant is
outstanding, (i) the Company effects any merger of the Company with or into another entity and the Company is not the
surviving entity (such surviving entity, the “Successor Entity”), (ii) the Company effects any sale of all
or substantially all of its assets in one or a series of related transactions, (iii) any tender offer or exchange offer
(whether by the Company or by another individual or entity, and approved by the Company) is completed pursuant to which
holders of Common Stock are permitted to tender or exchange their shares of Common Stock for other securities, cash or
property and the holders of at least 50% of the Common Stock accept such offer, or (iv) the Company effects any
reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of
shares of Common Stock) (in any such case, a “Fundamental Transaction”), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive the number of shares of Common Stock of the Successor
Entity or of the Company and any additional consideration (the “Alternate Consideration”) receivable upon
or as a result of such reorganization, reclassification, merger, consolidation or disposition of assets by a holder of the
number of shares of Common Stock for which this Warrant is exercisable immediately prior to such event (disregarding
any limitation on exercise contained herein solely for the purpose of such determination). For purposes of any such exercise,
the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the
amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative
value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as
to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. To the
extent necessary to effectuate the foregoing provisions, any Successor Entity in such Fundamental Transaction shall issue to
the Holder a new warrant consistent with the foregoing provisions and evidencing the Holder’s right to exercise such
warrant into Alternate Consideration.

  

    5

     

    

 

4.
 NON-CIRCUMVENTION. The Company covenants and agrees that it will not, by amendment
of its certificate of incorporation, bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of
arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant
and take all action as may be required to protect the rights of the Holder. Without limiting the generality of the foregoing,
the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above
the Exercise Price then in effect, (ii) shall take all such actions as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and non-assessable shares of Common Stock upon the exercise of this Warrant, and (iii)
shall, for so long as this Warrant is outstanding, have authorized and reserved, free from preemptive rights, three (3) times
the number of shares of Common Stock into which the Warrants are then exercisable into to provide for the exercise of the rights
represented by this Warrant (without regard to any limitations on exercise).

 

5.
 WARRANT HOLDER NOT DEEMED A STOCKHOLDER. Except as otherwise specifically provided
herein, this Warrant, in and of itself, shall not entitle the Holder to any voting rights or other rights as a stockholder of
the Company. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase
any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted
by the Company or by creditors of the Company.

 

6. REISSUANCE.

 

(a)
 Lost, Stolen or Mutilated Warrant. If this Warrant is lost, stolen, mutilated
or destroyed, the Company will, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case
of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as this Warrant so
lost, stolen, mutilated or destroyed.

 

(b)
 Issuance of New Warrants. Whenever the Company is required to issue a new Warrant
pursuant to the terms of this Warrant, such new Warrant shall be of like tenor with this Warrant, and shall have an issuance date,
as indicated on the face of such new Warrant which is the same as the Issuance Date.

 

7.
 TRANSFER. This Warrant shall be binding upon the Company and its successors and
assigns, and shall inure to be the benefit of the Holder and its successors and assigns. Notwithstanding anything to the contrary
herein, the rights, interests or obligations of the Company hereunder may not be assigned, by operation of law or otherwise, in
whole or in part, by the Company without the prior signed written consent of the Holder, which consent may be withheld at the
sole discretion of the Holder (any such assignment or transfer shall be null and void if the Company does not obtain the prior
signed written consent of the Holder). This Warrant or any of the severable rights and obligations inuring to the benefit of or
to be performed by Holder hereunder may be assigned by Holder to a third party, in whole or in part, without the need to obtain
the Company’s consent thereto.

  

    6

     

    

 

8.
 NOTICES. Whenever notice is required to be given under this Warrant, unless otherwise
provided herein, such notice shall be given in accordance with the notice provisions contained in the Purchase Agreement. The
Company shall provide the Holder with prompt written notice (i) immediately upon any adjustment of the Exercise Price, setting
forth in reasonable detail, the calculation of such adjustment and (ii) at least 20 days prior to the date on which the Company
closes its books or takes a record (A) with respect to any dividend or distribution upon the shares of Common Stock, (B) with
respect to any grants, issuances or sales of any stock or other securities directly or indirectly convertible into or exercisable
or exchangeable for shares of Common Stock or other property, pro rata to the holders of shares of Common Stock or (C) for determining
rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information
shall be made known to the public prior to or in conjunction with such notice being provided to the Holder.

 

9.
 AMENDMENT AND WAIVER. The terms of this Warrant may be amended or waived (either
generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company
and the Holder.

 

10.
GOVERNING LAW AND VENUE. This Warrant shall be governed by and construed in accordance with the laws of the State of Nevada
without regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions
contemplated by this Warrant shall be brought only in the state courts located in New York, NY or federal courts located in New
York, NY. The parties to this Warrant hereby irrevocably waive any objection to jurisdiction and venue of any action instituted
hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. EACH
PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY
DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT ENTERED INTO IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT, ANY
OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY. The prevailing party shall be entitled to recover
from the other party its reasonable attorney’s fees and costs. In the event that any provision of this Warrant or any other
agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such
provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with
such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity
or enforceability of any other provision of any agreement. Each party hereby irrevocably waives personal service of process and
consents to process being served in any suit, action or proceeding in connection with this Agreement or any other Transaction
Document by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law.

 

11.
 ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute acceptance
of and agreement to all of the terms and conditions contained herein.

 

12.
 CERTAIN DEFINITIONS. For purposes of this Warrant, the following terms shall
have the following meanings:

 

(a) “Nasdaq”
means www.Nasdaq.com.

 

(b)
 “Closing Sale Price” means, for any security as of any date,
(i) the last closing trade price for such security on the Principal Market, as reported by Nasdaq, or, if the Principal
Market begins to operate on an extended hours basis and does not designate the closing trade price, then the last trade price
of such security prior to 4:00 p.m., New York time, as reported by Nasdaq, or (ii) if the foregoing does not apply, the last
trade price of such security in the over-the-counter market for such security as reported by Nasdaq, or (iii) if no last
trade price is reported for such security by Nasdaq, the average of the bid and ask prices of any market makers for such
security as reported by the OTC Markets. If the Closing Sale Price cannot be calculated for a security on a particular date
on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as
mutually determined by the Company and the Holder. All such determinations to be appropriately adjusted for any stock
dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

  

    7

     

    

 

(c)
 “Common Stock” means the Company’s common stock, and any other
class of securities into which such securities may hereafter be reclassified or changed.

 

(d)
 “Common Stock Equivalents” means any securities of the Company that
would entitle the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock,
rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise
entitles the holder thereof to receive, Common Stock.

 

(e)
 “Dilutive Issuance” is any issuance of Common Stock or Common Stock
Equivalents described in Section 2(b) above; provided, however, that a Dilutive Issuance shall not include any Exempt Issuance.

  

(f)
 “Exempt Issuance” means the issuance of (i) shares of Common Stock
or options to employees, officers, or directors of the Company pursuant to any stock or option plan duly adopted by a majority
of the non-employee members of the Board of Directors of the Company or a majority of the members of a committee of non-employee
directors established for such purpose, (ii) securities issued pursuant to acquisitions approved by a majority of the disinterested
directors of the Company, and (iii) shares of Common Stock issued pursuant to any real property leasing arrangement.

 

(g)
 “Principal Market” means the primary national securities exchange
on which the Common Stock is then traded.

 

(h)
 “Market Price” means the highest traded price of the Common Stock
during the ninety Trading Days prior to the date of the respective Exercise Notice.

 

(i)
 “Trading Day” means (i) any day on which the Common Stock is listed
or quoted and traded on its Principal Market, (ii) if the Common Stock is not then listed or quoted and traded on any national
securities exchange, then a day on which trading occurs on any over-the-counter markets, or (iii) if trading does not occur on
the over-the-counter markets, any Business Day.

 

13. MOST
FAVORED NATION. While any portion of this Warrant remains unexercised, the Company shall not enter into any public or
private offering of its securities (including securities convertible into shares of Common Stock) with any individual or
entity (an “Other Investor”) that has the effect of establishing rights or otherwise benefiting such Other
Investor in a manner more favorable to such Other Investor than the rights and benefits established in favor of the Holder by
this Warrant unless, in any such case, the Holder has been provided with such rights and benefits pursuant to a definitive
written agreement or agreements between the Company and the Holder. From the date hereof and for so long as any portion of
this Warrant remains unexercised, in the event that the Company issues or sells any Common Stock or Common Stock Equivalents
or issues, any other securities convertible into, exercisable for, or otherwise entitle any person or entity the right to
acquire, shares of Common Stock, if the Holder then holding any unexercised portion of this Warrant, believes that any of the
terms and conditions appurtenant to such issuance or sale are more favorable to such investor(s) than are the terms and
conditions granted to the Holder, then such additional or more favorable term, at Holder’s option, shall automatically
become a part of the transaction documents (including but not limited to this Warrant) with the Holder. The Company shall
provide the Holder with notice of any such issuance or sale not later than two (2) Trading Days before such issuance or
sale.

 

*
* * * * * *

   

 

 

    9

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be duly executed as of the Issuance Date set forth above.

  

	 	BIOXYTRAN, INC.
	 	 
	 	 
	 	Title: Chief Executive Officer

  

    10

     

    

 

EXHIBIT
A

 

EXERCISE
NOTICE

 

(To
be executed by the registered holder to exercise this Common Stock Purchase Warrant)

  

The
Undersigned holder hereby exercises the right
to purchase _________________ of the shares of Common Stock (“Warrant Shares”) of BIOXYTRAN, INC., a Nevada
corporation (the “Company”), evidenced by the attached copy of the Common Stock Purchase Warrant (the “Warrant”).
Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.

 

		1.	Form
of Exercise Price. The Holder intends that payment of the Exercise Price shall be made as (check one):

 

☐
a cash exercise with respect to _________________ Warrant Shares; or

☐
by cashless exercise pursuant to the Warrant.

  

		2.	Payment
of Exercise Price. If cash exercise is selected above, the holder shall pay the applicable Aggregate Exercise Price in
the sum of $___________________ to the Company in accordance with the terms of the Warrant.

 

		3.	Delivery
of Warrant Shares. The Company shall deliver to the holder __________________ Warrant Shares in accordance with the terms
of the Warrant.

  

Date:

  

	 	 
	 	(Print Name of Registered Holder)
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

  

    11

     

    

 

EXHIBIT
B

 

ASSIGNMENT
OF WARRANT

 

(To
be signed only upon authorized transfer of the Warrant)

 

For
Value Received, the undersigned hereby sells,
assigns, and transfers unto ____________________ the right to purchase _______________ shares of common stock of BIOXYTRAN,
INC., to which the within Common Stock Purchase Warrant relates and appoints ____________________, as attorney-in-fact, to transfer
said right on the books of BIOXYTRAN, INC. with full power of substitution and re-substitution in the premises. By accepting such
transfer, the transferee has agreed to be bound in all respects by the terms and conditions of the within Warrant.

  

Dated:
__________________

  

	 	 
	 	(Signature) *
	 	 
	 	 
	 	(Name)
	 	 
	 	 
	 	(Address)
	 	 
	 	 
	 	(Social Security or Tax Identification No.)

 

*
The signature on this Assignment of Warrant must correspond to the name as written upon the face of the Common Stock Purchase
Warrant in every particular without alteration or enlargement or any change whatsoever. When signing on behalf of a corporation,
partnership, trust or other entity, please indicate your position(s) and title(s) with such entity.Exhibit 10.1

 

EXCHANGE AGREEMENT

 

THIS EXCHANGE AGREEMENT (this “Agreement”)
is made and entered into as of the 9 day of January, 2020 (the “Effective Date” or “date hereof”),
by and among Bonus BioGroup Ltd., a company incorporated under the laws of the State of Israel (“Bonus”),
on the one hand; and Wize Pharma Inc., a company incorporated under the laws of the State of Delaware, USA (“Wize
Inc.” or “Investor”); on the other hand. Each of the parties to this Agreement is referred to as a
“Party” and, collectively, as the “Parties”.

 

	WHEREAS,	 	concurrently with the execution of this Agreement, Bonus and Wize Inc. are entering into that certain Share Purchase Agreement dated as of even date hereof (the “SPA”), under which Bonus has undertaken to issue to Wize Inc. and Wize Inc. has undertaken to purchase from Bonus, the Bonus Shares (as defined therein), under the terms and conditions described therein;
	 	 	 
	WHEREAS,	 	Bonus desires to purchase, and Wize Inc. desires to sell, the Right to LO2A Proceeds (as defined below), in consideration for the LO2A Shares (as defined in the SPA), under the terms and conditions described herein; and
	 	 	 
	WHEREAS,	 	the Parties have agreed that the simultaneous closing of this Agreement is one of the conditions precedent to the consummation of the transactions contemplated by the SPA.

 

NOW, THEREFORE, in consideration
of the mutual promises and covenants set forth herein, the Parties hereby agree as follows:

 

1.
Definitions. 

 

For
purposes of this Agreement, (i) capitalized terms not otherwise defined herein shall have the meaning ascribed to such terms in
the SPA and (ii) the following terms will have the following meanings:

 

“Confidential Information”
means any scientific, technical, trade or business information relating to the subject matter of this Agreement designated as confidential,
or which otherwise should reasonably be construed under the circumstances as being confidential disclosed by or on behalf of a
Party hereto or any of its or its Affiliates’ employees or officers, whether in oral, written, graphic or machine-readable
form, except to the extent such information: (i) was known to the receiving Party or its Affiliates at the time it was disclosed,
as evidenced by such Party’s written records at the time of disclosure; (ii) is at the time of disclosure or later becomes
publicly known under circumstances involving no breach of this Agreement; (iii) is lawfully and in good faith made available to
the receiving Party or its Affiliates by a third party who is not subject to obligations of confidentiality with respect to such
information; or (iv) is independently developed without the use of or reference to Confidential Information, as demonstrated by
documentary evidence.

 

     

     

    

 

“Intellectual Property
Rights” or “IPR” means any and all intellectual property rights, including without limitation (i)
patents and patent applications, including all reissues, renewals, reexaminations, extensions, supplementary protection certificates
or equivalents thereof, continuations, divisions, and continuations-in-part thereof; (ii) copyrights and all other rights corresponding
thereto throughout the world; (iii) rights associated with trademarks, service marks, trade names, trade dress, domain names,
logos and similar rights, and the goodwill associated therewith, whether registered or unregistered; (iv) trade secrets and
know-how (viii) any similar, corresponding or equivalent rights to any of the foregoing anywhere in the world, including without
limitation, the right to seek remedies against infringements thereof and rights of protection of an interest therein under the
laws of all jurisdictions.

 

“Invoicing Entity”
means Wize IL and OcuWize as well as any LO2A Affiliate.

 

“LO2A Affiliate”
means Wize IL, OcuWize or any other Affiliate of Wize IL or OcuWize that receives any rights to the LO2A Technology or the LO2A
Proceeds.

 

“LO2A Agreement”
means that Exclusive Distribution and Licensing Agreement between Wize IL (including OcuWize) and Resdevco, dated as of May 1,
2015, as amended and supplemented until the date hereof.

 

“LO2A Proceeds”
means (i) the total amounts invoiced by or on behalf of, or otherwise due to, any Invoicing Entity, in cash or in kind, generated
as a result of the exploitation of the LO2A Technology or any part thereof in any manner whatsoever, including but not limited,
in consideration for the sale, lease, conveyance, transfer, rental
or other disposal of products and/or grant of rights by any Invoicing
Entity to the LO2A Technology or otherwise related to the LO2A Technology, after deduction of: (a) cost of goods solely
with respect to those Products invoiced in the relevant invoice; (b) sales taxes (including value added taxes, excise taxes, customs
duties and similar indirect taxes on sales) to the extent applicable to such sale and included in the sale invoice; (c) freight,
shipping and insurance charges in respect of such sale to the extent such items are separately itemized on invoices; and (d) credits
or allowances actually granted on account of recalls, rejections or returns of Products previously sold; provided that: (A) in
the event of sale of a Product between two Invoicing Entities for subsequent sale of such Product to a third party, the LO2A Proceeds
shall be the greater of: (x) the actual amount charged for the sale of such Product between such Invoicing Entities; and (y) the
amount invoiced by or on behalf of, or otherwise due to, an Invoicing Entity for such sale of such Product to an unrelated third
party, in each case, after the deductions specified above, to the extent applicable; (B) in the event an Invoicing Entity receives
non-cash consideration for a Product, or the LO2A Proceeds shall be the fair market value of such non-cash consideration; and (C)
license fees, royalties and other consideration payable under the LO2A
Agreement to Resdevco shall be excluded from LO2A Proceeds; and (ii) the consideration payable in a Sale Transaction or
in connection therewith without deduction of any expenses.

 

“LO2A Technology”
means any invention, know-how or other Intellectual Property Rights owned by or licensed to Wize Group and/or any of its Affiliates
prior to, on and/or after the date hereof in connection with, based on and/or as a result of the use of the formula developed by
Resdevco for the treatment of dry eye syndrome, and other ophthalmological illnesses, including Conjunctivochalasis and Sjögren’s
syndrome.

 

    2

     

    

 

“Wize Material Adverse
Effect” means any (A) material adverse effect or change, on or affecting (i) the business (including the LO2A Technology
and LO2A Proceeds), properties, assets, liabilities, operations, results of operations, condition (financial or otherwise) or prospects
of Wize Inc. and its Subsidiaries, taken as a whole, or (ii) the transactions contemplated hereby or the other Transaction Documents
or by the agreements and instruments to be entered into in connection herewith or therewith, or (iii) on the authority or ability
of Wize Inc. to perform its obligations under the Transaction Documents, or (iv) on the legality, validity, binding effect or enforceability
of any of the Transaction Documents; provided, however, that “Wize Material Adverse Effect” shall not include
any event, occurrence, fact, condition or change, directly or indirectly, arising out of or attributable to: (i) general economic
or political conditions; (ii) conditions generally affecting the industries in which Wize Group operates; (iii) any changes
in financial, banking or securities markets in general, including any disruption thereof and any decline in the price of any market
index or any change in prevailing interest rates; (iv) acts of war (whether or not declared), armed hostilities or terrorism,
or the escalation or worsening thereof; (v) any changes in applicable laws or accounting rules following the date hereof; (vi) the
public announcement or completion of the Transactions contemplated by this Agreement (provided that no such announcement shall
be in violation of the terms hereof); (vii) any natural disaster or acts of God; (viii) any failure by Wize Group to
meet any internal or published projections, forecasts or revenue or earnings predictions (provided that the underlying causes of
such failure shall not be excluded); or (ix) any changes in the share price of Wize Inc. (provided that the underlying causes of
such changes shall not be excluded); except in the case of (i), (ii), (iii), (iv), (v) or (vii) above to the extent these effects
or changes do not have a disproportionate effect or change on Wize Group as compared to other Persons in the industries in which
Wize Group operates.

 

“M&A Transaction”
means (i) the liquidation, dissolution or winding up of Wize IL and/or
OcuWize; (ii) a merger or acquisition of Wize IL and/or OcuWize
with or into, any other entity or person. Notwithstanding the foregoing, the term M&A Transaction shall not include any transaction
or series of related transactions that are part of an internal voluntary reorganization and/or restructuring of the Wize Group
or any entity in the Wize Group that does not involve the acquisition of control by a third party not affiliated with the Wize
Group, such the merger of OcuWize with and into Wize IL or vice versa.

 

“OcuWize”
means OcuWize Ltd., a company incorporated under the laws of the State of Israel and a wholly owned subsidiary of Wize IL.

 

“Product”
means (i) all products, that comprise, contain or incorporate, in whole or in part, LO2A Technology, or (ii) the development, production
and/or sale of which is based on, or involves, in whole or in part, the use of LO2A Technology or (iii) products which are produced
or manufactured, in whole or in part, using a process, method or system covered by, or falling within, the LO2A Technology; or
(iv) any other use, commercialization and/or exploitation of the LO2A Technology in any manner whatsoever and for any purpose or
indication whatsoever with respect to all of the foregoing.

 

“Resdevco”
means Resdevco Ltd.

 

“Sale
Transaction” means (i) the sale of shares of Wize IL
and/or OcuWize to a third party that is not an Affiliate of Wize Group; (ii) an M&A Transaction; (iii) the sale of assets
of Wize IL and/or OcuWize, or of the portion of Wize IL’s
and/or OcuWize’s business or assets relating to the LO2A
Technology; (iv) any transaction or series of related transactions pursuant to which persons or entities (who were not, prior to
such transaction, shareholders of Wize IL) acquire issued and outstanding shares of Wize IL or the right to appoint or elect at
least fifty percent (50%) of the directors of Wize IL, and/or (v) any of the above transactions if undertaken by an Affiliate of
Wize IL to which the Wize IL has licensed the LO2A Technology. For the sake of clarity, an issuance or sale of shares of Wize Inc.
itself (not shares of Wize IL or OcuWize or any other LO2A Affiliate),
or assets of Wize Inc. that are not directly related to the LO2A Technology or to the LO2A Proceeds, does not constitute a Sale
Transaction, except as specified in Section 5.4 below. Notwithstanding the foregoing, the term Sale Transaction shall not include
any transaction or series of related transactions that are part of an internal voluntary reorganization and/or restructuring of
Wize Group that does not involve the acquisition of control by a third party not affiliated with Wize Group, such the merger of
OcuWize with and into Wize IL, or vice versa.

 

    3

     

    

 

“Wize IL”
means Wize Pharma Ltd., a company incorporated under the laws of the State of Israel and a wholly owned subsidiary of Wize Inc.

 

“Wize Group”
means Wize Inc., Wize IL and OcuWize.

 

2.
The Transaction

 

2.1
General. Upon the terms and subject to the conditions set forth herein, at the Closing (as defined below), Bonus shall purchase
from Wize Inc., and Wize Inc. shall grant to Bonus, the Right to LO2A Proceeds, in consideration for the issuance of the LO2A Shares
in accordance with the terms set forth herein. 

 

2.2
Stock Splits, Etc. In the event of any stock split, bonus shares, consolidation, share dividend (including any dividend
or distribution of securities convertible into share capital), reorganization, reclassification, combination, recapitalization
or other like change with respect to the Ordinary Shares occurring after the date hereof and prior to the Closing, all references
in this Agreement to numbers of LO2A Shares and all related calculations shall be equitably adjusted to the extent necessary to
provide to Wize Inc. the same economic effect as contemplated by this Agreement.

 

3.
Closing Conditions; Termination, Etc. 

 

3.1
Mutual Closing Conditions. The obligations of each party to consummate the transactions contemplated hereunder, including
the issuance of the LO2A Shares and the grant of the Right to LO2A Proceeds (the “Transaction”),
is subject to the simultaneous occurrence of the Closing (as defined in the SPA).

 

3.2
Bonus Closing Conditions. The obligations of Bonus to consummate the Transaction is subject to the satisfaction (or waiver
in writing by Bonus) of all of the following conditions precedent (the “Bonus Closing Conditions”):

 

3.2.1
The representations and warranties of Wize Inc. set forth herein shall be true and correct in all material respects as of the date
hereof and as of the Closing Date, as if made at and as of such time (in each case, except to the extent expressly made as of an
earlier date, in which case as of such date) except for those representations and warranties that are qualified by materiality
and except for those representations and warranties in Sections 10.5 and 10.6, all of which shall be true and correct in all respects.

 

3.2.2
Wize Inc. shall have performed or complied in all material respects with all covenants and obligations required by this Agreement
to be performed or complied with by it on or prior to the Closing Date.

 

3.2.3
From the date hereof until the Closing, there will have been no Wize Material Adverse Effect.

 

    4

     

    

 

3.3
Wize Closing Conditions. The obligations of Wize Inc. to consummate the Transaction is subject to the satisfaction (or waiver
in writing by Wize Inc.) of all of the following conditions precedent (the “Wize Closing Conditions”
and together with the Mutual Closing Conditions and the Bonus Closing Conditions, the “Closing Conditions"):

 

3.3.1
The representations and warranties of Bonus set forth herein shall be true and correct in all material respects as of the date
hereof and as of the Closing Date, as if made at and as of such time (in each case, except to the extent expressly made as of an
earlier date, in which case as of such date), except for those representations and warranties that are qualified by materiality
and except for those representations and warranties in Sections 5.1.1, 5.2 and 5.3 of the SPA, all of which shall be true and correct
in all respects.

 

3.3.2
Bonus shall have performed or complied in all material respects with all covenants and obligations required by this Agreement to
be performed or complied with by it on or prior to the Closing Date.

 

3.4
Termination. This Agreement may be terminated at any time before the Closing as follows:

 

3.4.1
By mutual written consent of the parties;

 

3.4.2
In the event that the Closing shall not occur on or before the Outside Time (as defined in the SPA), either party may terminate
this Agreement by written notice to the other party; provided that the party seeking to terminate this Agreement pursuant to this ‎Section
shall not have breached in any material respect its obligations under this Agreement in any manner that shall have caused the failure
to consummate the Closing on or before such date; or

 

3.4.3
In the event that Wize Inc. shall have not either (i) deposited the Cash Consideration with the Escrow Agent or (ii) provided evidence
that it has received the Cash Consideration (whether in its own bank account or in an account administered by an escrow agent who
may be the Escrow Agent), in each case, by no later than the Confirmation Time (as defined in the SPA), either party may, within
24 hours thereafter, terminate this Agreement by written notice to the other party.

 

3.5
Effect of Termination. Any termination of this Agreement under ‎Section
3.4 above will be effective immediately upon written notice of the terminating party to the other parties hereto specifying the
provision of this Agreement on which such termination is based. If this Agreement is terminated as provided in ‎Section
3.4 this Agreement shall forthwith become void and shall have no further effect, without any liability or obligation on the part
of either party, this Section 3.5 and ‎Section 12 shall survive any termination
of this Agreement in accordance with their respective terms.

 

4. Closing.

 

4.1
Closing Date. The closing of the sale and purchase of the LO2A Shares (the “Closing”)
shall take place at 10:00 a.m., local time (Israel) electronically via the exchange of documents and signatures, within no later
than the second (2nd) Business Day immediately following the satisfaction (or wavier, by the party entitled to provide such waiver)
of all the Closing Conditions (other than those respective conditions that by their nature are to be satisfied only at the Closing),
or such other date and time as the Parties agree in writing (the date on which the Closing actually takes place, the “Closing
Date”).

 

    5

     

    

 

4.2
Closing Deliverables. At the Closing, the following actions will take place, all of which shall be deemed to have occurred
simultaneously and no transaction shall be deemed to have been completed or any document delivered until all such transactions
have been completed and all required documents delivered: 

 

4.2.1
Bonus will issue and allocate the LO2A Shares in the name of the Nominee (on behalf of the Investor, to be deposited with the Investor’s
securities account).

 

4.2.2
Bonus shall deliver to Wize Inc. all such other closing deliverables as set forth in Section 4 of the SPA, with respect to the
LO2A Shares. 

 

5.
The Right to LO2A Proceeds 

 

5.1
Subject to, and effective as of, Closing, Wize Inc. hereby grants Bonus the irrevocable right to receive thirty seven percent (37.0%)
(the “Agreed Percentage”) of the Wize Group’s (and of any other LO2A
Affiliate) LO2A Proceeds (the “Right to LO2A Proceeds”), which will be remitted
to Bonus by Wize Inc. (or the Invoicing Entity) in accordance with Section 6 below. 

 

5.2
Bonus’ Right to the LO2A Proceeds shall be in effect for an unlimited period of time, except as otherwise set forth below.

 

5.3
It is hereby clarified that, if the LO2A Proceeds are generated from a Sale Transaction, then such payment (of the Agreed Percentage
of the LO2A Proceeds) shall be a one-time and final payment (and the Right to LO2A Proceeds shall terminate); provided however
that if the Sale Transaction includes, directly or indirectly, any further payments, whether monetary or otherwise, including fees,
royalties and lump sum payments payable to Wize Inc., Wize IL and/or any LO2A Affiliate following the consummation of the Sale
Transaction, then Bonus shall continue to be entitled to the Agreed Percentage of the LO2A Proceeds to which the Invoiced Entity
continues, if any, to be entitled thereafter. By way of illustration of the foregoing only, if (A) Wize Inc. sells all of
the shares of Wize IL for a purchase price that consists of cash payable at closing, then Bonus shall be entitled to a one-time
final payment equal to the Agreed Percentage thereof, (B) Wize Inc. sells all of the shares of Wize IL for a purchase price that
consists of cash payable at closing and earnout payments, then Bonus shall be entitled to a one-time payment equal to the Agreed
Percentage of the cash payable at closing and the Agreed Percentage of the earnout amount if and when actually received, and (C)
if Wize IL sells 75% of its rights to the LO2A Technology for cash payable at closing, then Bonus shall be entitled to a one-time
payment equal to the Agreed Percentage of the cash payable at closing and continue to be entitled to the Agreed Percentage of the
LO2A Proceeds to which the Invoicing Entity shall continue to be entitled following such transaction.

 

5.4
Notwithstanding anything to the contrary in this Agreement, it is hereby agreed that in the event of a Sale Transaction of Wize
Inc. that involves a sale of its shares in an M&A Transaction or similar change of control transaction (the “Parent
COC”), Bonus shall be entitled, at Bonus’ sole discretion, to elect, by delivery
of an irrevocable written notice to Wize Inc. (the “Election Notice”) to either
(i) remain with its right to the Agreed Percentage of the LO2A Proceeds or (ii) terminate the Right to LO2A Proceeds and receive
a one-time and final payment based on the proceeds paid in such transaction, which payment will be equal to the Agreed Percentage
of the LO2A Value (“LO2A Value” means the value attributed to Wize IL out
of the total proceeds payable for Wize Inc. in such transaction), which LO2A Value shall be determined by BDO Israel or, if BDO
Israel is not able or not willing to serve, another independent third party appraiser retained by the Parties (the “COC
Appraiser”), at the expense of Wize Inc. In this respect, the parties further agree as
follows:

 

    6

     

    

 

5.4.1
The Election Notice shall be provided no later than seven (7) Business Days following written notice by Wize Inc. (the “Wize
COC Notice”); it being agreed that (i) the Wize COC Notice shall set forth the material
terms of the Parent COC, including the proposed purchase price, form and manner of payment (together, the “COC Pricing
& Payment Terms”); (ii) to the extent available at the time of delivery of the Wize
COC Notice, the notice shall include a copy of any signed term sheet, letter of intent or acquisition agreement; (iii) the information
in such Wize COC Notice shall be kept confidential by Bonus; (iv) if Bonus fails to timely deliver the Election Notice, Wize Inc.
shall be entitled to elect, in its sole discretion, either clause (i) or (ii) of Section 5.4 above; and (v) if the Wize COC Notice
was delivered prior to the signing of a binding acquisition agreement and, since the delivery thereof, the COC Pricing & Payment
Terms are modified in any material respects (the “Pricing Terms Modification”),
then Wize Inc. shall deliver to Bonus a new Wize COC Notice and the aforesaid procedure shall apply again, except that the period
for Bonus to provide the Election Notice shall be three (3) Business Days.

 

5.4.2
The COC Appraiser will be engaged within seven (7) days following delivery of the Wize COC Notice and its determination of the
LO2A Value shall be delivered, in writing, within 14 days following engagement thereof; it being understood that, in the event
that, during such engagement, there is a Pricing Terms Modification, the Appraiser shall deliver its valuation within 14 days following
delivery of the notice regarding such Pricing Terms Modification. The COC Appraiser’s determination of the LO2A Value shall
be final and binding on the parties. For the sake of clarity, the inability of the Parties to agree on the identity of the COC
Appraiser (if BDO Israel is not able or not willing to serve) or, without derogating from the second sentence of this Section 5.4.2,
any dispute regarding the LO2A Value shall not entitle Bonus to delay or prevent the consummation of any Sale Transaction.

 

5.5
Wize Inc. undertakes to use its reasonable commercial efforts, taking into account Wize Group’s financial position and capabilities,
to commercialize (or cause OcuWize or Wize IL, as applicable, to commercialize) the LO2A Technology or any part thereof in any
manner whatsoever, including but not limited, by the sale, lease, conveyance, transfer, rental or other disposal of products and/or
grant of rights to the LO2A Technology or otherwise generate the LO2A Proceeds.

 

5.6
Notwithstanding anything contrary hereunder (including Section 5.8) or under the SPA but without derogating from the parties’
representations and warranties set forth herein or therein, nothing herein shall be construed as (i) any representation, warranty
or guarantee by Wize Inc. or any Person on its behalf that it or any other LO2 Affiliate will be able to generate LO2A Proceeds
at all, or, if any are generated, their scope or timing, (ii) granting Bonus any rights to direct, be consulted or otherwise being
involved with respect to, the development or commercialization actions of Wize Group in connection with the LO2A Technology (including
a Sale Transaction for this matter), or (iii) granting or assigning Bonus any of OcuWize’s or its Affiliates rights under
the LO2A Agreement, or for Bonus assuming any of OcuWize’s or its Affiliates obligations under the LO2A Agreement.

 

5.7
Subject to, and effective as of, Closing, Wize Inc. undertakes that, for as long as this Agreement and the Right to LO2A Proceeds
has not terminated or expired in accordance with the terms hereof: (i) Wize Group shall not create, incur, or permit to exist any
Lien (as defined below) on the Right to LO2A Proceeds, and (ii) Wize Group shall not enter into any agreements which would allow
the creation or attachment of a Lien upon the Right to LO2A Proceeds, in each case, other than as contemplated under Section 5.8
below.

 

    7

     

    

 

5.8
Subject to, and effective as of, Closing, Wize Inc. undertakes as follows:

 

5.8.1
Wize Inc. shall cause, and take all actions necessary (including, but not limited to, using its voting power therein) to cause,
Wize IL and OcuWize to perform and take such acts as may be necessary for Wize Inc. to comply with the provisions of this Agreement,
including, but not limited to, ensuring that any Agreed Percentage of the LO2A Proceeds is transferred to Bonus in accordance with
this Agreement. 

 

5.8.2
As promptly as possible following the Closing and, in any event, not later than 30 days following the Closing, it shall secure
and cause Wize IL and OcuWize to secure the obligation of Wize Inc.’s grant of the Right to LO2A Proceeds hereunder by (i)
in the case of Wize Inc., filing a UCC lien and (ii) in the case of Wize IL and OcuWize, registering with the Israeli Companies
Registrar, a fixed first degree lien, in each case, over their respective rights in the Agreed Percentage of the LO2A Proceeds,
in form and substance reasonably acceptable to Bonus. 

 

5.8.3
In the event of a Sale Transaction, which, in accordance with this Agreement, the payment of the Agreed Percentage of the LO2A
Proceeds payable to Bonus hereunder in such transaction is not a one-time and final payment (e.g., there are contingent payment
following the consummation of the Sale Transaction), the acquirer or successor entity in such Sale Transaction shall provide a
written statement to Bonus to the effect that such acquirer assumes responsibility for the payment, in accordance with this Agreement,
of the amounts, if any, that will become payable to Bonus under this Agreement following the consummation of the Sale Transaction.

 

6.
Payment of LO2A Proceeds 

 

6.1 Timing.
Within ten (10) Business Days after receipt of any LO2A Proceeds by any Invoicing Entity, Wize Inc. (or the Invoicing Entity) shall
remit to Bonus all amounts due hereunder with respect to such LO2A Proceeds.

 

6.2 Payment Currency.
All payments in respect of LO2A Proceeds due under this Agreement shall be payable in the same currency received by the Invoicing
Entity or, at Wize Inc.’s election, U.S. Dollars unless otherwise agreed in writing by Bonus and Wize Inc.. Conversion of
foreign currency to U.S. Dollars, if applicable, shall be made at the conversion rate as published by the Bank of Israel on the
last Business Day prior to the applicable payment date. Notwithstanding anything to the contrary, it is hereby agreed that, in
the case of LO2A Proceeds received in the form of securities or other non-cash property in a Sale Transaction, Wize Inc. shall
pay (or cause the payment) the LO2A Proceeds due under this Agreement in the same form of consideration received by it (or by the
applicable LO2A Affiliate) in such Sale Transaction.

 

6.3 Late Payments.
Any payments by Wize Inc. (or the applicable Invoicing Entity) due to Bonus with respect to the LO2A Proceeds that are not paid
on or before the date such payments are due under this Agreement shall bear interest beginning on the 30th day following
the due date thereof, calculated at the monthly rate of (i) one percent (1.0%) in the first 30 days of delay and (ii) two percent
(2.0%) thereafter, compounded monthly; provided, however, that in no event shall such monthly interest rate exceed the maximum
rate allowed under applicable law. Interest shall accrue beginning on the 30th day following the due date for payment.
Payment of such interest by the applicable Invoicing Entity shall not limit, in any way, Bonus’ right to exercise any other
remedies Bonus may have as a consequence of the lateness of any payment.

 

    8

     

    

 

6.4 Taxes Etc.
All payments made to Bonus hereunder shall be made free and clear of any withholding taxes, levies and/or any other taxes or duties
as may be required by applicable law and, other than pursuant to the SPA, any set-off or counterclaim, subject to receipt of valid
tax exemptions.

 

7.
Reports

 

7.1 Within thirty
(30) days after the conclusion of each calendar quarter, commencing with the first calendar quarter in which any LO2A Proceeds
are generated, Wize Inc. shall deliver (or cause to be delivered) to Bonus a report containing the following information (in each
instance, with a Product-by-Product and country-by-country breakdown):

 

7.1.1
the number of units of Products sold by any Invoicing Entity for the applicable calendar quarter;

 

7.1.2
the gross amount billed or invoiced for Products sold by any Invoicing Entity during the applicable calendar quarter;

 

7.1.3
a calculation of LO2A Proceeds for the applicable calendar quarter, including an itemized listing of applicable deductions; and

 

7.1.4
the total amount payable to Bonus in respect of LO2A Proceeds for the applicable calendar quarter, together with the exchange rates
used for conversion, if applicable.

 

7.2 Each such report
shall be certified on behalf of Wize Inc. as true, correct and complete in all material respects.

 

7.3 If no amounts
are due to Bonus for a particular calendar quarter, the report shall include a statement to such effect.

 

8.
Records; Audit 

 

8.1 Wize Inc. shall
maintain, and shall cause its LO2A Affiliates to maintain, complete and accurate records of Products that are made, used, or sold,
any amounts payable to Bonus in relation to such Products, which records shall include a country-by-country and Product-by-Product
breakdown and shall contain sufficient information to reasonably permit the Auditor (as defined below) to confirm the accuracy
of any reports or notifications delivered to Bonus under Section 7 above. Wize Inc. shall, and shall cause its LO2A Affiliates,
if any, to retain such records relating to a given calendar quarter for at least three (3) years after the conclusion of that calendar
quarter.

 

8.2 Bonus shall have
the right, at its expense, to cause an independent, certified public accountant (the “Auditor”), selected by
Bonus and reasonably acceptable to Wize Inc., to inspect such records during normal business hours and upon reasonable prior written
notice for the sole purposes of verifying the accuracy of any reports delivered under Section 7 of this Agreement (and, consequently,
payments payable to Bonus hereunder), in respect of any report delivered to Bonus not more than three (3) years prior to the date
of such Bonus’ written notice.

 

8.3 Such Auditor shall
not disclose to Bonus any information other than information relating to the accuracy of reports and payments delivered under this
Agreement. The Auditor shall be required to execute a confidentiality agreement in form and substance reasonably satisfactory to
Wize Inc. prior to commencing any such audit. Bonus acknowledges that the Auditor shall conduct its audit in such a manner so as
to not unreasonably interfere with Wize Inc.’s or its Affiliates’ business.

 

    9

     

    

 

8.4 The Parties shall
reconcile any underpayment or overpayment within thirty (30) days after the Auditor delivers the results of the audit. In the event
that any audit performed under this Section 8 reveals an underpayment in excess of five percent (5%) in any calendar year, Wize
Inc. shall bear the reasonable cost of such audit. Any overpayment to Bonus shall be fully creditable against future payments payable
in subsequent periods; provided that, in the event there is no further obligation to pay Bonus hereunder, Bonus shall pay Wize
Inc. the portion of such overpayment not credited within thirty (30) days after such obligation ceased.

 

8.5 Bonus may exercise
its auditing rights under this Section 8 only once every year per audited entity. Upon the expiration of three (3) years following
the delivery of any report to Bonus, the calculation of payments payable hereunder to Bonus with respect to such report shall be
final, binding and conclusive upon the Parties.

 

8.6 Notwithstanding
anything to the contrary hereunder, the audit rights under this Section 8 and the reporting requirements under Section 7 shall
terminate within one year following a Sale Transaction in which the Right to LO2A Proceeds terminates, except that any pending
audits or disputes regarding a report shall continue until finally resolved.

 

9.
Representations and Warranties of Bonus

 

Bonus
hereby represents, confirms and warrants to Wize Inc. that the following representations shall be true, correct and complete as
of the execution date of this Agreement and as of the Closing (except to the extent expressly made as of an earlier date, in which
case as of such date), except as set forth in the Company Disclosure Letter delivered to Wize Inc. on the date hereof (such disclosures
being considered to be made for purposes of the specific sub-Section of the Company Disclosure Letter in which they are made and
for purposes of all other Sections only to the extent the relevance of such disclosure is reasonably apparent on its face):

 

9.1 General.
Bonus makes (and reiterates) the same representations and warranties set forth in Section 5 of the SPA as of the date hereof and
as of the Closing.

 

9.2 Experience.
Bonus has the knowledge and experience in financial, industry, business and Intellectual Property Rights matters, such that it
is capable of evaluating the merits and risks of the Transaction and its implied investment in the commercialization of the LO2A
Technology. Without derogating from the representations and warranties of Wize Inc. in Section 10 below, Bonus further acknowledges
that (i) it has been provided with, and understand, the SEC Documents and (ii) it had an adequate opportunity to ask questions
of, and receive answers from, Wize Group as well as Wize Group’s officers, employees, agents and other representatives concerning
the LO2A Technology and all other matters relevant to the Transaction.

 

9.3 Consents.
Bonus has obtained all consents and authorizations that shall be necessary or required lawfully for its execution, delivery and
performance of this Agreement and the other Transaction Documents (including the issuance of the Bonus Shares), except for receipt
of the TASE Approval. 

 

9.4 No Other Representations
or Warranties. Except for the representations and warranties contained in this Section 9 and in any certificate delivered by
Bonus hereunder (including the SPA), neither Bonus nor any other Person on behalf of Bonus or its Subsidiaries makes any other
express or implied representation or warranty with respect to Bonus or its Subsidiaries or with respect to any other information
provided by or on behalf of Bonus or its Subsidiaries.

 

    10

     

    

 

10.
Representations and Warranties of Wize Inc. –

 

Wize
Inc. hereby represents, confirms and warrants to Bonus that the following representations shall be true, correct and complete as
of the execution date of this Agreement and as of the Closing (except to the extent expressly made as of an earlier date, in which
case as of such date), except as set forth in the Wize Disclosure Letter delivered to Bonus on the date hereof (such disclosures
being considered to be made for purposes of the specific sub-Section of the Wize Disclosure Letter in which they are made and for
purposes of all other Sections only to the extent the relevance of such disclosure is reasonably apparent on its face):

 

10.1 General.

 

10.1.1 Experience.
Without derogating from the representations and warranties made by Bonus, Wize Inc. represents that it has made its own assessment
of the present condition and the future prospects of Bonus and is sufficiently experienced to make an informed judgment with respect
thereto.

 

10.1.2 Acquisition
for Own Account. Wize Inc. is acquiring the LO2A Shares as principal for its own account for investment purposes only and not
with an immediate view to or for distributing or reselling such LO2A Shares or any part thereof, without prejudice, however, to
Wize Inc.’s right at all times to sell or otherwise dispose of all or any part of such LO2A Shares in compliance with applicable
securities laws, including lock up provisions prescribed by applicable laws and regulations.

 

10.1.3 Brokers;
Fees and Expenses. Except for H.C. Wainwright & Co., LLC, a true and complete copy of which engagement letter has been
made available to Bonus, there is no investment banker, broker, finder or similar agent or other Person that has been retained
by or is authorized to act on behalf of Wize Inc. or any of its Subsidiaries who is entitled to any financial advisor, brokerage,
finder or other similar fee or commission in connection with the transactions contemplated hereby.

 

10.2 SEC Documents;
Financial Statements. Since January 1, 2018, Wize Inc. has timely filed all reports, schedules, forms, statements and other
documents required to be filed by it with the SEC pursuant to the reporting requirements of the 1934 Act (all of the foregoing
filed prior to the date hereof or prior to the Closing Date, and all exhibits included therein and financial statements, notes
and schedules thereto being hereinafter referred to as the “SEC Documents”). As of their respective filing dates,
the SEC Documents complied in all material respects with the requirements of applicable law, including the 1934 Act, applicable
to the SEC Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of
a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. As of their respective filing dates, the
financial statements of Wize Inc. included in the SEC Documents complied as to form in all material respects with applicable accounting
requirements and the published rules and regulations of the SEC with respect thereto as in effect as of the time of filing. Such
financial statements have been prepared in accordance with U.S. GAAP, consistently applied, during the periods involved (except
(i) as may be otherwise indicated in such financial statements or the notes thereto, or (ii) in the case of unaudited interim statements,
to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present in all material respects
the financial position of Wize Inc. and its Subsidiaries as of the dates thereof and the results of its operations and cash flows
for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments which will not be
material either individually or in the aggregate).

 

    11

     

    

 

10.3 Subsidiaries.
Wize Inc. holds 100% of the outstanding share capital of Wize Ltd. Wize Ltd. holds 100% of the outstanding share capital of OcuWise.

 

10.4 LO2A Technology.
Wize Inc., via Ocuwize, sponsors a study, a true and correct copy of the protocol of which, as of the date hereof, in Section
10.4 of the Wize Disclosure Letter.

 

10.5 Organization
and Qualification. Each of Wize Inc., Wize IL and OcuWize is an entity duly organized and validly existing and in good standing
(excluding for purposes of the representation regarding good standing, any entity formed in Israel) under the laws of the jurisdiction
in which they are formed, and have the requisite power and authorization to own their properties and to carry on their business
as now being conducted and as presently proposed to be conducted.

 

10.6 Authorization;
Enforcement; Validity. Wize Inc. has the requisite corporate power and authority to enter into and perform its obligations
under this Agreement, including but not limited to the sale of the Right to LO2A Proceeds, and each of the Transaction Documents
in accordance with the terms hereof and thereof. The execution and delivery of this Agreement and the other Transaction Documents
by Wize Inc. and the consummation by Wize Inc. of the transactions contemplated hereby and thereby, including, without limitation,
the grant of Right to LO2A Proceeds, have been duly authorized by Wize Inc. Board of Directors and no further consent or authorization
is required from Wize Inc., its Board of Directors or its shareholders. This Agreement and the other Transaction Documents have
been duly executed and delivered by Wize Inc., and constitute the legal, valid and binding obligations of Wize Inc., enforceable
against Wize Inc. in accordance with their respective terms, except as such enforceability may be limited by the Bankruptcy and
Equity Exceptions.

 

10.7 No Conflicts.
The execution, delivery and performance of the Transaction Documents by Wize Inc. and the consummation by Wize Inc. of the transactions
contemplated hereby and thereby will not (i) result in a violation of the Articles of Association of Wize Inc. or its Subsidiaries,
any memorandum of association, certificate of incorporation, certificate of formation, bylaws, any certificate of designations
or other constituent documents of Wize Inc. or any of its Subsidiaries, or (ii) conflict with, or constitute a default (or an event
which with notice or lapse of time or both would become a default) in any respect under, or give to others any rights of termination,
amendment, acceleration or cancellation of, any material agreement, indenture or instrument to which Wize Inc. or any of its Subsidiaries
is a party, including the LO2A Agreement or (iii) result in a violation of any law, rule, regulation, order, judgment or decree
applicable to Wize Inc. or any of its Subsidiaries or by which any property or asset of Wize Inc. or any of its Subsidiaries is
bound or affected.

 

10.8 Permits.
Except as set forth in the SEC Documents, (i) Wize Group is in compliance with the terms of all permits, licenses, authorizations,
consents, approvals and franchises from governmental authorities required to conduct its business as currently conducted in connection
with the LO2A Technology (“Permits”), and no suspension or cancellation of any such Permits is pending or, to
the knowledge of Wize Inc., threatened, except for such non-possession, noncompliance, suspensions or cancellations that have not
had, individually or in the aggregate, a Wize Material Adverse Effect, and (ii) except for matters that have not had, individually
or in the aggregate, a Wize Material Adverse Effect, Wize Group has not received written notice from a governmental authority of
any legal proceeding relating to (x) any actual or alleged violation of, or failure to comply with, any term or requirement of
any such Permit or (y) any withdrawal, suspension, cancellation, termination, nonrenewal or modification of any such Permit.

 

    12

     

    

 

10.9 Absence of
Certain Changes. Since September 30, 2019, there has been no Wize Material Adverse Effect.

 

10.10 No Undisclosed
Events, Liabilities, Developments or Circumstances. As of the date hereof, other than the Transactions, no event, liability,
development or circumstance has occurred or exists, or is contemplated to occur, that would be required to be disclosed by Wize
Inc. under applicable securities laws, which has not been publicly announced.

 

10.11 Consents.
Wize Group has obtained all consents and authorizations that shall be necessary or required lawfully for its execution, delivery
and performance of this Agreement and the other Transaction Documents (including the grant of the Right to LO2A Proceeds to Bonus).
 

 

10.12 Absence of
Litigation. Except as set forth in the SEC Documents, there is no action, suit, or proceeding before or by any court, public
board, government agency, self-regulatory organization or body, pending or, to the knowledge of Wize Inc., threatened against Wize
Group with regard to the LO2A Technology and/or LO2A Agreement, or any of Wize Inc.’s or its Affiliates’ officers or
directors, whether of a civil or criminal nature or otherwise, in their capacities as such, except for actions, suits or proceedings
which would not, individually or in the aggregate, reasonably be expected to have a material impact on Wize Group (including the
LO2A Technology).

 

10.13 Intellectual
Property Rights. To Wize Inc.’s knowledge (without conducting any independent investigation, including any patent search),
(i) Resdevco has sole ownership of the Licensed Technology (as defined in the LO2A Agreement), (ii) the Licensed Technology (as
defined in the LO2A Agreement) is valid and (iii) there is no legal proceeding pending, or being threatened, against Resdevco or
Wize Group claiming that the Licensed Technology (as defined in the LO2A Agreement) infringes the Intellectual Property Rights
of any third party. OcuWize holds a valid license to use the Intellectual Property Rights relating to the LO2A Technology as set
forth in the LO2A Agreement and, other than its rights under the LO2A Agreement, Wize Group does not have any other rights in the
LO2A Technology. There is no claim, action or proceeding being made or brought, or to the knowledge of Wize Inc., being threatened,
against Resdevco or Wize Group that the LO2A Technology infringes the Intellectual Property Rights of any third party. Wize Group
has taken reasonable security measures to protect the secrecy, confidentiality and value of all of its Intellectual Property Rights.

 

10.14 Absence of
Liens and Encumbrances. Wize Group has a valid right in the Licensed Technology (as defined in the LO2A Agreement) and LO2A
Proceeds in accordance with the LO2A Agreement and, at Closing, shall grant Bonus the Right to LO2A Proceeds free and clear of
any liens, pledges, charges, security interests or encumbrances, third party rights, rights of first refusal or similar rights
(collectively, “Liens”), provided that it is hereby clarified that the foregoing shall not be deemed as a representation
regarding Intellectual Property Rights (the representations of which are set forth in Section 10.13 above).

 

10.15 LO2A Agreement.
The LO2A Agreement is in full force and effect and is valid, binding and enforceable in accordance with its terms, except as such
enforceability may be limited by the Bankruptcy and Equity Exceptions. Wize Group is in compliance in all material respects with,
and is not otherwise in breach, violation or default, in any material respect, of the terms or conditions of the LO2A Agreement
(including time lines, schedules, time of performance requirements and other milestones under the LO2A Agreement), nor to Wize
Inc. knowledge, has there occurred any event or occurrence that would constitute a breach, violation or default (with or without
the lapse of time, giving of notice or both) by OcuWize (or any Affiliate thereof, including Wize IL and Wize Inc.) of the LO2A
Agreement, in any material respect. To Wize Inc.’s knowledge, no material breach of any of the terms or conditions of the
LO2A Agreement by Resdevco has occurred. Wize Inc. has delivered to Bonus an accurate and complete copy of the LO2A Agreement.

 

    13

     

    

 

10.16 No Other
Representations or Warranties. Except for the representations and warranties contained in this Section 10 and in any certificate
delivered by Wize Inc. hereunder, neither Wize Inc. nor any other Person on behalf of Wize Inc. or their Affiliates makes any other
express or implied representation or warranty with respect to Wize Inc. or its Affiliates, including the LO2A Technology, or with
respect to any other information provided by or on behalf of Wize Inc. or its Affiliates.

 

11.
Notice of Events.

 

11.1 During the period
from the date of this Agreement and until the earlier of the Closing Date and the valid termination of this Agreement, (i) Bonus
shall notify Wize Inc. promptly following becoming aware of (A) any inaccuracy in or breach of any of its representations, warranties
or covenants contained in this Agreement which would reasonably be expected to cause any of the Mutual Closing Conditions or Wize
Closing Conditions not to be timely (or at all) satisfied and (B) any other event, condition, fact or circumstance that would make
the timely satisfaction of any of the Mutual Closing Conditions or Wize Closing Conditions impossible or unlikely; and (ii) Wize
Inc. shall notify Bonus promptly following becoming aware of (A) any inaccuracy in or breach of any of its representations, warranties
or covenants contained in this Agreement which would reasonably be expected to cause any of the Mutual Closing Conditions or Bonus
Closing Conditions not to be timely (or at all) satisfied and (B) any other event, condition, fact or circumstance that would make
the timely satisfaction of any of the Mutual Closing Conditions or Bonus Closing Conditions impossible or unlikely.

 

11.2 If any event,
condition, fact or circumstance that is required to be disclosed pursuant to Section 11.1 requires any change in the Company Disclosure
Letter or the Wize Disclosure Letter, as applicable, or if any such event, condition, fact or circumstance would require such a
change assuming the Company Disclosure Letter or the Wize Disclosure Letter, as applicable, was dated as of the date of the occurrence,
existence or discovery of such event, condition, fact or circumstance, then Bonus or Wize Inc., as applicable, may (but are not
obligated to) deliver to the other party a written update to the Company Disclosure Letter or the Wize Disclosure Letter, as applicable,
specifying such change. In this respect, it is hereby agreed that (a) no such notice or update shall be deemed to supplement or
amend the Company Disclosure Letter, or the Wize Disclosure Letter, as applicable, for the purpose of determining whether any of
the Closing Conditions has been satisfied and (b) such notice or update shall be deemed to supplement or amend the Company Disclosure
Letter, or the Wize Disclosure Letter, as applicable, for the purpose of determining the accuracy of any of the representations
and warranties made by Bonus or Wize Inc. in this Agreement (including for purpose of any remedy for a breach thereof hereunder),
only if (i) such notice or update is with respect to factual updates of the Company Disclosure Letter or the Wize Disclosure Letter,
as applicable, regarding events that occurred following the date hereof and (ii) despite receipt of such notice, Bonus or Wize
Inc., as the case may be, determined to proceed with the Closing.

 

    14

     

    

 

12.
Miscellaneous

 

12.1
Amendment. No change and/or amendment to this Agreement or any of the provisions thereof shall be valid and/or binding unless
made in writing and was signed by the parties to this Agreement.

 

12.2
Entire Agreement. This Agreement together with the Transaction Documents, as such term is defined under the SPA, contains
and exhausts the full and entire understanding, agreement and relations between the parties hereto with regard to the subject matters
hereof, and shall supersede, in their entirety, any prior document, negotiations, declaration, representation, undertaking or consent
with regard to the subject matters contained herein, whether made in writing and/or verbally, expressly and/or implicitly and/or
in any other way, prior to execution of this Agreement, including the non-binding Term Sheet entered into between the parties on
October 10th, 2019 (as amended from time to time).

 

12.3
English version governs; Construction. This Agreement may be translated into another language, as a comfort translation. 
However, between this version and any other translated version of this Agreement, the English version shall prevail. The headings
herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the
provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express their
mutual intent, and no rules of strict construction will be applied against any party. This Agreement shall be construed as if drafted
jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provisions of this Agreement. When used in this Agreement, (i) references to “$” or “Dollars” are
references to U.S. dollars; (ii) the words “hereof,” “herein” and “herewith” and words of similar
import will, unless otherwise stated, be construed to refer to this Agreement as a whole and not to any particular provision of
this Agreement; (iii) the words “include,” “includes” and “including” will be deemed in each
case to be followed by the words “without limitation”.

 

12.4
Governing Law; Jurisdiction. The laws of the State of Israel shall apply and govern this Agreement. Exclusive jurisdiction
in all matters pertaining to and in connection with this agreement shall be vested in the competent courts of Tel Aviv, Israel.

 

12.5
Assignment. Other than as set forth in this Agreement, no party to this Agreement may assign, transfer or encumber, in any
way or form, its rights or obligations pursuant to this Agreement, in whole or in part, without the prior written consent of the
other parties to this Agreement; provided, however, that (i) Wize Inc. may make the assignment(s) as permitted under Section 13.5
of the SPA and (ii) Wize Inc. may assign its rights and obligations under this Agreement to the acquirer in a Sale Transaction
that involves the sale of assets of Wize IL and/or OcuWize, or of the portion of Wize IL’s and/or OcuWize’s business
or assets relating to the LO2A Technology, to such acquirer (other than the obligation, if any, to be paid a portion of the LO2A
Proceeds arising in such Sale Transaction in accordance with Section 5 hereof).

 

12.6
Notice. All notices, requests and other communications required or permitted under, or otherwise made in connection with,
this Agreement, shall be in writing to the address set forth below and shall be deemed to have been duly given upon the earlier
of actual receipt, or (i) personal delivery to the party to be notified, (ii) when sent, if sent by electronic mail (or, if indicated
below, facsimile) during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s
next Business Day, (iii) five (5) days after having been sent by registered mail, return receipt requested, postage prepaid, or
(iv) one (1) Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business
day delivery, with written verification of receipt, in each case, addressed to the parties’ addresses as set forth herein.
Each party may change its address for the purposes of this Agreement, by providing a written notice that shall be sent or delivered
to the other party at its address.

 

    15

     

    

 

If to Bonus:

 

Bonus BioGroup Ltd.

Matam Advanced Technology Park,
Building 8B, 6th floor,

P.O.B. 15143, Haifa 3190501, Israel

E-mail: office@bonus-bio.com

Attention: Dr. Shai Meretzki and
Yossi Rauch

 

with required
copies (which shall not constitute notice) to:

 

Dr. Shai Meretzki

E-mail: shaime@bonus-bio.com

 

and

 

Yossi Rauch

E-mail: yossira@bonus-bio.com

 

and

 

Efrati Galili Confino & Co.

Address: 28 Haarbaa St. | Haarbaa
South Tower

| 19th floor | Tel Aviv 6473925

Attention: Gil
Lavron, Adv.

Email: gil@egl.co.il

 

If to Wize Inc.:

 

Wize Pharma, Inc.

24 Hanagar Street

Hod Hasharon, Israel 4527708

E-mail: noam@wizepharma.com; or@wizepharma.com

Attention: CEO and CFO

 

with required copies (which shall not constitute notice)
to:

 

Goldfarb Seligman & Co.

Ampa Tower, 98 Yigal Alon Street

Tel Aviv 67891, Israel

E-mail: ido.zemach@goldfarb.com

Attention: Ido Zemach, Adv.

 

12.7
Binding Effect; Benefit; Assignment. The provisions of this Agreement and any other Transaction Document, as the case may
be, is intended for the benefit of the parties hereto and their respective successors and permitted assigns, shall be binding upon
and shall inure to the benefit of the parties hereto and thereto and their respective permitted successors and assigns and is not
for the benefit of, nor may any provision hereof be enforced by, any other Person. 

 

    16

     

    

 

12.8
Counterparts. This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same
effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become effective when each party
hereto shall have received a counterpart hereof signed by all of the other parties hereto. The exchange of a fully executed Agreement
(in counterparts or otherwise) by electronic transmission in PDF format or by facsimile shall be sufficient to bind the parties
hereto to the terms and conditions of this Agreement.

 

12.9
Remedies. All rights and remedies of any party hereto under this Agreement are cumulative and the exercise of one or more
of such rights or remedies shall not prejudice or impair the concurrent or subsequent exercise of other such rights or remedies
given hereunder or now or hereafter existing at law or in equity or otherwise. 

 

12.10
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
or other authority to be invalid, void, unenforceable or against its regulatory policy, the remainder of the terms, provisions,
covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or
invalidated.

 

12.11
Specific Performance. Notwithstanding anything to the contrary herein, the parties hereto agree that irreparable damage
may occur if any provision of this Agreement were not performed in accordance with the terms hereof and that the parties hereto
shall be entitled to an injunction or injunctions to prevent breaches of this Agreement or to enforce specifically the performance
of the terms and provisions of this Agreement in addition to any other remedy to which they are entitled at law or in equity.

 

12.12
Survival of Warranties; Limitation of Liability. All representations and warranties made by Bonus and Wize Inc. shall survive
the Closing and remain in full force and effect for a period of 24 months following the Closing, provided, however, that the representations
and warranties contained in Sections 5.1.1, 5.2 and 5.3 of the SPA and Sections 10.5 and 10.6 of this Agreement shall survive
the Closing and shall expire thirty (30) days after the expiration date of the applicable statute of limitations. In no event shall
either party be liable to the other for consequential, special, punitive or indirect damages.

 

12.13
Publicity. Each of the parties hereto shall coordinate with each other all publicity relating to the transactions contemplated
by this Agreement, and shall not issue any press release, immediate report or other filing with the ISA or the U.S. SEC relating
to this Agreement or the transactions contemplated by this Agreement without first obtaining the prior consent of the other or
its representative, except that neither party shall be precluded from timely making such filings or giving such notices as may
be required by applicable law or the rules of any stock exchange. Each of the parties hereto shall cooperate and shall use their
reasonable efforts to agree on the form and substance of the report to be filed by Bonus with the ISA and Wize Inc. with the U.S.
SEC relating to the transactions contemplated by this Agreement.

 

12.14
Delays or Omissions. Except as otherwise specifically provided for hereunder, no party shall be deemed to have waived any
of his or her or its rights hereunder or under any other agreement, instrument or document signed by any of them with respect to
the subject matter hereof unless such waiver is in writing and signed by the party waiving said right. Except as otherwise specifically
provided for hereunder, no delay or omission by any party in exercising any right with respect to the subject matter hereof shall
operate as a waiver of such right or of any such other right. A waiver on any one occasion with respect to the subject matter hereof
shall not be construed as a bar to, or waiver of, any right or remedy on any future occasion. All rights and remedies with respect
to the subject matter hereof, whether evidenced hereby or by any other agreement, instrument or document, will be cumulative, and
may be exercised separately or concurrently.

 

[Signature Page follows]

 

    17

     

    

 

IN WITNESS WHEREOF, the Parties
hereto have duly executed this Exchange Agreement as of the Effective Date.

 

	/s/ Yossi Rauch	 	/s/ Shai Meretzki
	 	 	 
	Bonus BioGroup Ltd.	 	 
	 	 	 
	By: Yossi Rauch	 	By: Shai Meretzki
	Title: Executive Chairman	 	Title: CEO and Director
	 	 	 
	/s/ Noam Danenberg	 	/s/ Or Eisenberg
	 	 	 
	Wize Pharma Inc.	 	 
	 	 	 
	By: Noam Danenberg	 	By: Or Eisenberg
	Title: CEO	 	Title: CFO & COO

 

 

18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]